Hormonal Tedavilerde Yan Etkiler ve Yönetimi
Özet
Hormon reseptör pozitif meme kanseri tedavisinde hormonal tedaviler gerek adjuvan dönemde gerekse metastatik dönemde yaygın şekilde kullanılan etkin tedavilerdir. Bu tedavileri kullanan hastalar tedavi sürecinde yan etkiler açısından takip edilmelidir. Onkolojik açıdan kontrol sağlanırkan yan etki nedeniyle olabilecek komplikasyonlar hastanın yaşam kalitesini etkileyebilmektedir. Bu tedavileri belirlerken hastanın menopoz durumu, kemik dansitesi, kardivasküler durumu gibi çeşitli faktörlere dikkat edilmektedir. Tamoksifen ile karşılaştırıldığında aromataz inhibitörleri daha yüksek osteoporoz, kırık, kardiyovasküler hastalık, diyabet ve hiperkolesterolemi riski ile ilişkilidir. Tamoksifen tedavisinde ise endometriyal kanser ve tromboembolik olaylarda artış görülebilmektedir.
Referanslar
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS, a randomised trial. Lancet 2013;381(9869):805–816.
Cardoso F, Parke S, Brennan DJ, et al. Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer. N Engl J Med 2025; 393:753.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.
Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst 2010; 102:942.
Hong N, Yoon HG, Seo DH, et al. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. Eur J Cancer 2017; 82:103.
6.Ricciardi E, Vecchione A, Marci R, et al. Clinical factors and malignancy in endometrial polyps. Analysis of 1027 cases. Eur J Obstet Gynecol Reprod Biol 2014; 183:121.
Buzdar AU. Pharmacology ve pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 2003;9(1 Pt 2):468–472.
Morales L, Pans S, Verschueren K, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008; 26:3147.
Arem H, Sorkin M, Cartmel B, et al. Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study. J Cancer Surviv 2016; 10:654.
Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012; 30:936.
Henry NL, Unger JM, Schott AF, et al. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 2018; 36:326.
Hershman DL, Unger JM, Greenlee H, et al. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA 2018; 320:167.
Early Breast Cancer Trialists’ Collaborative G. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341–1352.
Amir E, Seruga B, Nira S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review ve meta- analysis. J Natl Cancer Inst 2011;103(17):1299–1309.
Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27–a randomized controlled phase III trial. J Clin Oncol 2013;31:1398–1404.
Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation ve blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779–790.
Howell A, Robertson JFR, Albano JQ, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396–3403.
